Introduction {#sec1}
============

Spermatogenesis is the process to generate mature spermatozoa through three steps: mitosis, meiosis, and spermiogenesis. Mitotically proliferating diploid spermatogonia differentiate into primary spermatocytes, which divide twice with only one DNA replication to become haploid round spermatids through meiosis, and mature spermatozoa form by spermiogenesis \[[@bib1],[@bib2]\]. This series of events is tightly controlled by various genes, and genes activated in primary spermatocytes during meiosis are critical for spermatogenesis \[[@bib3]\]. Thus, elucidation of the mechanism of transcriptional activation at this stage is important for understanding spermatogenesis.

In the 1990s, several studies showed by generating transgenic mice that proximal promoters were sufficient for transcriptional activation of spermatocyte-specific genes \[[@bib6]\], but studies conducted in the 21st century indicated or suggested the necessity of distal enhancers \[[@bib12],[@bib13]\]. In agreement with the results of those studies, we identified a dual promoter−enhancer that functions in mouse spermatocytes to activate the spermatocyte-specific *Tcam1* gene and drive male germ cell-specific *lncRNA-Tcam1* and the ubiquitously expressed *Smarcd2* gene \[[@bib14]\]. In addition, recent genome-wide analyses have clearly shown that the testis expresses many more long noncoding RNAs (lncRNAs) than those expressed in other tissues \[[@bib15],[@bib16]\], and it has been shown that the noncoding transcription occurs at every step of meiosis \[[@bib17]\]. Because lncRNAs are key factors for gene activation in various cell types \[[@bib25]\], they are likely to play some roles in spermatocyte-specific gene activation, but the function of testicular lncRNAs is not well understood.

Long noncoding RNAs are a class of noncoding RNAs longer than 200 nucleotides, and they have been found to be present in the nuclei, cytoplasm, and extracellular vesicles (EVs) in various tissues \[[@bib30]\]. Generally, lncRNAs are not evolutionarily conserved, when compared with protein-coding genes \[[@bib36]\], and show tissue-specific expression \[[@bib15]\]. They are crucial regulators for transcription, RNA processing, translation, and construction of subnuclear structures in mammals \[[@bib39]\]. In the case of transcriptional activation, lncRNAs often function in cooperation with enhancers, and enhancers are therefore located close to lncRNAs for which transcription is necessary for promoter--enhancer interactions \[[@bib43],[@bib44]\]. Thus, in male germ cells, lncRNAs presumably contribute to transcriptional activation with enhancers.

We previously reported a testis-specific lncRNA, *lncRNA-HSVIII*, and two potential enhancers adjacent to it at the mouse *Prss/Tessp* gene cluster \[[@bib45]\]. The *Prss/Tessp* cluster is located on mouse chromosome 9F2-F3 and consists of three paralogous genes, *Prss42/Tessp-2, Prss43/Tessp-3*, and *Prss44/Tessp-4*, encoding serine proteases \[[@bib46]\]. They all are specifically activated in primary spermatocytes at the late pachytene stage, and *Prss42/Tessp-2* and *Prss43/Tessp-3* play important roles in the progression of meiosis and germ cell survival \[[@bib46]\]. *lncRNA-HSVIII* is transcribed in a testis-specific manner downstream of the *Prss42/Tessp-2* gene, and its localization changes from nuclei of primary spermatocytes to the cytosol of round spermatids during meiosis \[[@bib45]\]. The two potential enhancers were found upstream and downstream of *lncRNA-HSVIII*, but, interestingly, they did not seem to be functionally related to *lncRNA-HSVIII*. In the process of our study, we noticed that other intergenic regions were transcribed in a testis-specific manner at the *Prss/Tessp* locus, and those lncRNAs might participate in gene activation during meiosis.

In this study, we identified another testis-specific lncRNA, *Tesra* (*Tessp cluster lncRNA related to gene activation*), at the *Prss/Tessp* locus. *Tesra* was localized in the nuclei, cytoplasm, and extracellular regions of germ cells, and nuclear *Tesra* bound to the *Prss42/Tessp-2* promoter and increased its activity. In addition, an enhancer downstream of *lncRNA-HSVIII* co-functioned with *Tesra* to activate the *Prss42/Tessp-2* gene promoter. These findings contribute to an understanding of transcriptional activation during spermatogenesis and suggest a novel relationship between an lncRNA and an enhancer.

Materials and methods {#sec2}
=====================

Animals {#sec2-1}
-------

C57Bl/6Ncl mice (CLEA Japan Inc., Tokyo, Japan) were maintained on regular 14-h light/10-h dark cycles at 25°C and were given sufficient food and water. The experimental procedures used in this study were approved by the Institutional Animal Use and Care Committee at Hokkaido University.

Reverse transcription-polymerase chain reaction {#sec2-2}
-----------------------------------------------

Total RNA was extracted by ISOGEN, ISOGEN II, or ISOGEN-LS (Nippon Gene, Tokyo, Japan) according to the manufacturer\'s instructions. After treatment with TurboDNase (Life Technologies, Foster City, CA), the RNA was reverse-transcribed into complementary DNA (cDNA) using Superscript III (Life Technologies) based on the previously described method \[[@bib47],[@bib48]\]. PCR was performed by using ExTaq (Takara, Kusatsu, Japan). Primer sequences are shown in Table [1](#tbl1){ref-type="table"}.

###### 

Primers used in this study.

  Designation                                   Forward                        Reverse
  --------------------------------------------- ------------------------------ ------------------------------
  \[RT-PCR/qRT-PCR\]                                                           
  *Tesra* PCR                                   5′-CGTGCCTGTTTCTTTCCATT-3′     5′-CAGCCACCATGTTCTGTGAC-3′
  *Tesra* 2890bp                                5′-CGTGCCTGTTTCTTTCCATT-3′     5′-GTTGCATCTCCACCCATCA-3′
  *Tesra* full length                           5′-AGAGGTGTGAGGCTGGTGGG-3′     5′-TGAACATATTAAATGAGCTC-3′
  *Gapdh*                                       5′-CATGACCACAGTCCATGCCATC-3′   5′-TAGCCCAAGATGCCCTTCAGTG-3′
  \[5′RACE and 3′RACE\]                                                        
  GSP1                                                                         5′-CAGCCACCATGTTCTGTGAC-3′
  GSP2                                                                         5′-GGCAACCTGGAAAGGAAAAT-3′
  GSP3                                                                         5′-AATGGAAAGAAACAGGCACG-3′
  GSP4                                          5′-CCTGAAGCTCACCCCTAGTA-3′     
  GSP5                                          5′-TTGATGGGTGGAGATGCAAC-3′     
  \[RT-PCR/qRT-PCR with extracellular RNA\]                                    
  *Tesra* exosome                               5′-ACCAGGGCCAGGAATTTATC-3′     5′-TGTTCCCAGTGTTGGCTGTA-3′
  *lncRNA-HSVIII* exosome                       5′-TTGTCATTGGGGCAGAAATA-3′     5′-CACCACAAAAACAAAGGGTG-3′
  \[ChIRP-qPCR\]                                                               
  *Rec8* promoter                               5′-CCTTGGCGAAGTCCTTGTTA-3′     5′-AATAGTCGCCAGCCAATCAC-3′
  *B2m* promoter                                5′-GGCCAGGGGTTTAACTTCTC-3′     5′-CCCTTGGGGTTTCTGCTTAT-3′
  *Prss42/Tessp-2* promoter                     5′-GGTGCCTCTTTGGAGACCTA-3′     5′-GACCCCTTACTTCCTGTGGA-3′
  *Prss44/Tessp-4* promoter                     5′-CTTCTGCTGTCTGGGAGTCA-3′     5′-AACGGGTGGTTTCATTTAGC-3′
  *Prss43/Tessp-3* promoter                     5′-CTGCAGGTGACTCCACACTT-3′     5′-TTCCTCCTTCTGTCCCTCAG-3′
  intergenic *Prss42/Tessp2*-*Prss44/Tessp-4*   5′-CAGAGTCGCCTTCAAAATCC-3′     5′-TAGCCCAAATCAGCACCTTC-3′
  intergenic *Prss44/Tessp4*-*Prss43/Tessp-3*   5′-GAGGTACAGGCACAAGCACA-3′     5′-TAGCTGTGGCAGGCTTAGGT-3′
  *Prss45/TESPL* promoter                       5′-AGCACTAGGGGTGCTGTCAT-3′     5′-TGGACCCACTCTCGTCCTTA-3′
  *Prss46* promoter                             5′-TCAGTGGAGACTGGCATGAA-3′     5′-CCTGTGACCTTGTCCCTTGT-3′
  *Prss50/Tsp50* promoter                       5′-GCAGAGGAGGGTAGGGGTAT-3′     5′-TATGCCTCGCCTCAGCTAAT-3′

5′ and 3′ rapid amplification of cDNA ends {#sec2-3}
------------------------------------------

5′RACE (rapid amplification of cDNA ends) and 3′RACE were performed as previously described \[[@bib48]\]. For 5′RACE, cDNA was generated by using total RNA from adult mouse testes and a gene-specific primer (GSP1) for reverse transcription. After the addition of oligodeoxycytidine by terminal deoxynucleotidyl transferase (Takara), the first PCR was performed with GSP2 and an abridged anchor primer. The second PCR was performed using GSP3 and an abridged universal amplification primer.

For 3′RACE, reverse transcription was performed using the oligo(dT)~20~ primer connected to an adaptor sequence. The first and second PCRs were performed using GSP4 and GSP5, respectively, with the adaptor primer.

All GSP sequences are shown in Table [1](#tbl1){ref-type="table"}. Final PCR products were subcloned into a pBluescript II KS(+) vector (Stratagene, San Diego, CA) by the TA-cloning method, and their sequences were confirmed by DNA sequencing analysis.

Isolation of male germ cells, Sertoli cells, and Leydig cells {#sec2-4}
-------------------------------------------------------------

Isolation of male germ cells \[[@bib46]\], Sertoli cells \[[@bib49]\], and Leydig cells \[[@bib14]\] was performed as previously described. Sertoli cells were harvested from 7- to 12-day-old testes, and germ and Leydig cells were harvested from adult testes.

Preparation of subcellular fractions {#sec2-5}
------------------------------------

Cytoplasmic and nuclear fractions were obtained as previously described \[[@bib45],[@bib48]\]. Briefly, the cells were lysed in NP-40 lysis buffer (10 mM Tris-HCl, 10 mM NaCl, 3 mM MgCl~2~, 0.5% NP-40, pH 7.5) on ice for 10 min, and after centrifugation at 1500 rpm for 5 min at 4°C, the supernatant was used as the cytoplasmic fraction. The precipitates were washed two or three times with NP-40 lysis buffer, and the resulting pellet was used as the nuclear fraction.

Quantitative RT-PCR {#sec2-6}
-------------------

Complementary DNAs were prepared as described above. PCRs were performed by using Power SYBR Green PCR Master Mix for protein-coding genes (Life Technologies) and KOD SYBR qPCR Mix for lncRNAs (TOYOBO, Osaka, Japan), based on the previously described method \[[@bib14],[@bib47]\]. The relative expression levels were normalized to endogenous *Aip* mRNA, except for quantification of extracellular lncRNAs. The levels of *Tesra* and *lncRNA-HSVIII* in the extracellular fraction and germ cells were examined with primer pairs, *Tesra* exosome and *lncRNA-HSVIII* exosome, and directly compared because the amplification efficiencies of primer pairs for these lncRNAs were similar. For quantitative detection of *Tesra* in cells and tissues, a primer pair, *Tesra* PCR, was used, and for extracellular lncRNAs, other primer sets were used (Table [1](#tbl1){ref-type="table"}). The primers for *Prss/Tessp* cluster genes and *Aip* were described in our previous reports \[[@bib46],[@bib47]\].

In situ hybridization {#sec2-7}
---------------------

The RNA probes for detection of *Tesra* transcripts were prepared as follows. The full length of *Tesra* was obtained by RT-PCR with mouse testis cDNA and a primer pair of *Tesra* full length (Table [1](#tbl1){ref-type="table"}) using KOD Fx Neo (TOYOBO) and was subcloned into pBluescript II KS(+) which was cut by *Eco*RV. After the DNA sequence had been confirmed, a part of *Tesra* (1545--2363) was isolated by restriction digestion with *Xba*I and *Pvu*II, blunted by T4 DNA polymerase, and ligated into a blunted *Pst*I site of a pGEM-3Zf(+) vector. The resulting plasmid was linearized with *Apa*I or *Not*I for making sense and antisense RNA probes, respectively. Digoxigenin (DIG)-labeled RNA probes were synthesized using a DIG RNA labeling kit (Roche Molecular Biochemicals, Mannheim, Germany) with SP6 RNA polymerase for a sense probe and T7 RNA polymerase for an antisense probe.

In situ hybridization with the Tyramide Signal Amplification (TSA) Plus system (PerkinElmer, Waltham, MA) was performed according to the procedure reported previously \[[@bib45],[@bib50]\]. Briefly, adult mouse testes were fixed for 3 h at 4°C with 4% paraformaldehyde in phosphate buffered saline (PBS). After washing with PBS, the testes were dissected into two pieces with a razor blade under a dissecting microscope. The two pieces of testes were dehydrated, embedded in paraffin, and cut into 7-μm-thick sections. The sections were hybridized with 2 ng/μl of the DIG-labeled RNA probe overnight at 45°C. After washing, the sections were incubated with anti-DIG-horseradish peroxidase antibody (1:500 dilution; Roche) overnight at room temperature. The reaction with tyramide-Cy3 (1:50 dilution in 1X Plus Amplification Diluent \[PerkinElmer\], followed by 1:100 dilution with distilled water) was performed at room temperature for 20 min. To detect nuclei, the sections were incubated with 10 μg/ml Hoechst 33258 at room temperature for 10 min. The samples were mounted with a Fluoro-KEEPER Antifade Reagent (Nacalai Tesque, Kyoto, Japan) and observed under an LSM 5 LIVE confocal microscope (Carl Zeiss, Oberkochen, Germany).

Preparation of extracellular fractions and fractionation of extracellular vesicles {#sec2-8}
----------------------------------------------------------------------------------

Adult testes were decapsulated, cut 20 times with scissors, and put in Dulbecco modified Eagle medium. The tube was inverted 10 times and kept at room temperature for 2--3 min, and the supernatant was collected into a new tube. The samples were spun at 1000 g for 15 min at 4°C and filtered through a 0.45-μm filter. Then each sample was centrifuged at 10,000 *g* for 30 min to remove large EVs, and the resulting supernatant was used as the extracellular fraction.

The fraction of EVs was collected from the extracellular fraction by using the EV-second® column (GL Sciences, Tokyo, Japan), which could divide the samples by size exclusion chromatography. After blocking with filtered fetal bovine serum, the column was washed with PBS six times, and the sample was loaded on it. Elution was done with PBS, and 10 continuous fractions (200 μl each) were collected.

Western blot analysis {#sec2-9}
---------------------

A portion of the EV fraction (10 μl) was mixed with 4 × Laemmli sample buffer (\#1610747, Bio-Rad Laboratories, Hercules, CA) containing 10% β-mercaptoethanol and boiled at 94°C for 5 min. The samples were resolved by SDS--polyacrylamide gel electrophoresis using Any kD Mini-PROTEAN^®^ TGX^TM^ Precast Gel (\#4569036, Bio-Rad Laboratories) and then transferred onto polyvinylidene difluoride membranes (0.2-μm pore size; Bio-Rad Laboratories) via Trans-Blot^®^ Turbo^TM^ Transfer System (\#1704150, Bio-Rad Laboratories). The membranes were blocked with Blocking Reagent for WB (CSR-IS-CD-500W, Cosmo Bio Co., Ltd, Tokyo, Japan) at room temperature for 1 h and incubated with an anti-CD9 antibody (1:2000 dilution; ab92726, Abcam, Cambridge, MA) diluted in IMMUNO SHOT Platinum (CSR-IS-P-500, Cosmo Bio Co., Ltd) at 4°C overnight ([Supplemental Table S1](#sup1){ref-type="supplementary-material"}). The next day, the membranes were washed four times with 1 × Tris-buffered saline (20 mM Tris, 500 mM NaCl, pH 7.4) containing 0.1% Tween-20 (TBS-T) at room temperature and incubated with a secondary goat anti-rabbit immunoglobulin G-horseradish peroxidase conjugate (1:3000 dilution; \#7074, Cell Signaling Technology, Danvers, MA) diluted in IMMUNO SHOT Platinum (Cosmo Bio Co., Ltd) at room temperature for 1 h. The membranes were washed again with TBS-T four times, and signals were detected using Pierce^TM^ ECL Plus Western Blotting Substrate (\#32132, Thermo Fisher Scientific, Rockford, IL) and the Light Capture II system (AE-6981, ATTO Co., Tokyo, Japan).

Transmission electron microscopy {#sec2-10}
--------------------------------

An EV fraction that was positive for CD9 was fixed by adding an equal volume of 4% paraformaldehyde (2% at a final concentration). Ten microliters of the fixed sample was attached on a mesh using an Exosome-TEM-easy kit (Bio 101, Carlsbad, CA) according to the manufacturer\'s protocol. The EVs were visualized by a transmission electron microscope (H-7650, Hitachi, Tokyo, Japan).

Chromatin isolation by RNA purification {#sec2-11}
---------------------------------------

Thirteen antisense oligo probes for *Tesra* were designed by using singlemoleculefish.com 18 (<http://singlemoleculefish.com>) as indicated in Table [2](#tbl2){ref-type="table"}, and biotinylated at the 3′ end. Twenty million male germ cells were prepared from 21- to 22-day-old mice as described above. The cells in PBS were spun at 800--1000 rpm for 4 min, resuspended in 1% glutaraldehyde, and crosslinked for 10 min at room temperature on a rotator. The cross-linking reaction was quenched with a 1/10th volume of 1.25 M glycine at room temperature for 5 min. After washing the cells with PBS, a 10 × volume of the lysis buffer (final concentration of 50 mM Tris-Cl pH 7.0, 10 mM EDTA, 1% SDS) supplemented with phenylmethanesulfonyl fluoride, 1 × protease inhibitor (Wako Pure Chemicals, Osaka, Japan), and RNasin Plus (Promega, Madison, WI) was added to each tube. Then, the cell lysate was sonicated to shear the chromatin with 20% output for 10 s, 15 times, by using Ultrasonic Disruptor UD-201 (TOMY, Tokyo, Japan). The sample was spun at 15,000 rpm for 10 min at 4°C, and the supernatant was collected into another tube. One percent of this sample was taken as "input." Then the sample was hybridized with the combined oligo probes at the final concentration of 100 pmol/ml in hybridization buffer (750 mM NaCl, 1% SDS, 50 mM Tris-Cl pH 7.0, 1 mM EDTA, 15% formamide) at 37°C for 4 h with shaking. Streptavidin beads (GE Healthcare, Uppsala, Sweden) (100 μl per 100 pmol probe) were washed with the lysis buffer three times and resuspended in the same buffer supplemented with phenylmethanesulfonyl fluoride, 1 × proteinase inhibitor, and RNasin Plus. After the hybridization reaction, the beads were added to the tube and the sample was incubated at 37°C for 30 min with shaking. The beads were washed with 1 ml wash buffer (2 × NaCl and sodium citrate and 0.5% SDS) five times and resuspended in 1 ml wash buffer. One hundred microliters was set aside for RNA isolation, and the rest of the suspension (900 μl) was used for DNA extraction. Each tube was centrifuged at 4000 rpm for 1 min at room temperature, and the beads were collected. For the RNA sample, ISOGEN II was added and total RNAs were purified for qRT-PCR. For the DNA sample, 150 μl DNA elution buffer (50 mM NaHCO~3~, 1% SDS) was added with 1.0 μl of 10 mg/ml RNase A (Nacalai Tesque) and 0.3 μl of 10 U/μl RNase H (Bio Academia, Osaka, Japan), and the sample was incubated at 37°C for 30 min with shaking. The tubes were centrifuged at 4000 rpm, and the supernatant was collected in a new tube. This process was carried out twice. Fifteen microliters of 10 mg/ml Proteinase K (Nacalai Tesque) was added to the combined supernatants, and the sample was incubated at 50°C for 45 min. After the incubation, DNA was extracted by phenol-chloroform-isoamylalcohol and collected by alcohol precipitation. The input sample was treated with Proteinase K and extracted in the same way. The collected DNAs were subjected to quantitative PCR (qPCR) using Power SYBR Green PCR Master Mix (Life Technologies) with primers listed in Table [1](#tbl1){ref-type="table"}. The relative chromatin enrichment of each region was determined by calculating the ratio of the chromatin isolation by RNA purification (ChIRP) sample to the input sample, and the occupancy level was further normalized to the value at the *Rec8* promoter, which was set to 1.0. As a control, we prepared an RNase(+) sample that was treated with RNase in the hybridization reaction to reduce *Tesra* transcripts.

###### 

Tiling oligo probes used for ChIRP assay.

  Designation              Reverse
  ------------------------ ----------------------------
  \[ChIRP tiling oligo\]   
  ChIRP-1                  5′-CTAACATCTATCCTCTCCAA-3′
  ChIRP-2                  5′-GCCTCTAAAGTCAGGAGAAC-3′
  ChIRP-3                  5′-TCAAGGCAACCTGGAAAGGA-3′
  ChIRP-4                  5′-TACCAGTGCTTGACTTAGTA-3′
  ChIRP-5                  5′-GGCATTTCTTACTTCACACA-3′
  ChIRP-6                  5′-CCAGTCTCTTAGGGATTTAT-3′
  ChIRP-7                  5′-TACCTAACACTTCTTGCACT-3′
  ChIRP-8                  5′-ACTGGAGCAGCAAGAATTGC-3′
  ChIRP-9                  5′-GCTAGGCAAACTTCACCAAG-3′
  ChIRP-10                 5′-TCCACCCATCAAGACATTAA-3′
  ChIRP-11                 5′-AGAGAATTGGTGCCATGTTC-3′
  ChIRP-12                 5′-CTACTGCTCCGATGAAATGT-3′
  ChIRP-13                 5′-CAGTTTATTATCTGCTCACC-3′

Plasmid constructs {#sec2-12}
------------------

*Tesra-OE*: The full length of *Tesra* was subcloned into pBluescript II KS(+) as described above. The plasmid was digested with *Bam*HI and *Eco*RI, and the *Tesra* fragment was inserted into a pcDNA3.1(+) vector which was cut by *Bam*HI and *Eco*RI.

*T-2pro-luc*: This construct contained the luciferase gene driven by the *Prss42/Tessp-2* promoter as previously described \[[@bib45]\].

*T-2pro-luc-up and T-2pro-luc-down*: These constructs contained a 2.3-kb upstream or a 1.5-kb downstream sequence of *lncRNA-HSVIII* at the 3′ end of the luciferase gene in T-2pro-luc. They were both generated in our previous study \[[@bib45]\].

*Tesra-tet-on*: The full length of *Tesra* was obtained and subcloned into pBluescript II KS(+) as described above but in the opposite direction. This plasmid was digested with *Spe*I and *Xho*I, and the *Tesra* fragment was inserted into a pPBhCMV\*1-cHA-pA vector which was cut by *Spe*I and *Xh*oI \[[@bib51]\]. The pPBhCMV\*1-cHA-pA plasmid and other vectors required to establish the Tet-on system were kind gifts from Dr Kazuhiro Murakami \[[@bib51]\].

Cell culture and transfection {#sec2-13}
-----------------------------

Hepa1--6 cells were cultured as previously described \[[@bib14],[@bib47],[@bib52]\]. Transfection into Hepa1--6 cells was conducted according to the protocol of Genefectine (Genetrone Biotech, Seoul, South Korea) or GeneJuice transfection reagents (Merck, Darmstadt, Germany).

Overexpression of *Tesra* {#sec2-14}
-------------------------

For transient transfection, Tesra-OE was transfected into Hepa1--6 cells by using Genefectine. Selection was started 24 h after the transfection by treating the cells with 0.5--1.5 mg/ml G418. After selection for 3 days, the cells were dissolved in ISOGEN II, and total RNAs were purified for RT-PCR analyses. For a luciferase assay, T2pro-luc and pRL-CMV were co-transfected with Tesra-OE, and luciferase activity was measured 2 days later. In both experiments, pcDNA3.1(+) was used as a control.

For establishing the Tet-on system, we transfected Tesra-tet-on, pPBCAGrtTA-IN that bore a neomycin resistance gene, and pPyCAG-PBase into Hepa1--6 cells by GeneJuice. Twenty-four hours later, we selected successfully transfected cells by treating the cells with 2.0 mg/ml G418 for 24 days and established a stable cell line in which *Tesra* expression could be induced by the addition of Doxycycline (Dox). T2pro-luc, T-2pro-luc-up, or T-2pro-luc-down was transfected into these stable cells by GeneJuice, and 1.0 μg/ml Dox was added 1 day later. Twenty-four hours after the addition of Dox, the cells were used for a luciferase assay. The pRL-CMV vector (Promega) was co-transfected to normalize transfection efficiency.

Luciferase assay {#sec2-15}
----------------

The luciferase assay was conducted according to the protocol of Dual-Luciferase Reporter Assay System (Promega) as previously described \[[@bib27],[@bib47]\].

Statistical analysis {#sec2-16}
--------------------

Results were expressed as the average ± standard deviation (SD) of at least three independent experiments and were analyzed by the Student *t* test or one-way analysis of variance (ANOVA) followed by the Tukey post hoc test. A *P* value less than 0.05 was considered statistically significant.

Results {#sec3}
=======

Identification and characterization of an lncRNA, *Tesra*, at the mouse *Prss/Tessp* locus {#sec3-1}
------------------------------------------------------------------------------------------

Based on transcriptome data (accession numbers: SRX135150, SRX135160, and SRX135162), we found *lncRNA-HSVIII* downstream of the *Prss42/Tessp-2* gene in our previous study \[[@bib45]\]. The data also indicated many reads mapped to an intergenic region between *Prss44/Tessp-4* and *Prss43/Tessp-3* genes in the testis, suggesting the presence of other testis-specific noncoding transcripts at this locus. Thus, we performed RT-PCR with total RNA from mouse testes, and a 2890-nucleotide sequence was successfully amplified (Figure [1A](#fig1){ref-type="fig"}). We named this lncRNA *Tesra* and decided to determine its full length.

![Cloning of a novel lncRNA, *Tesra*. (A) A schematic view of the *Prss/Tessp* locus on mouse chromosome 9. Exons of three *Prss/Tessp* genes are depicted by the black and white boxes representing translated and untranslated regions, respectively. Two lncRNAs that do not contain any introns are also depicted by the black boxes. The bent arrows indicate the transcriptional direction. Below the gene structure, the genomic region transcribed into *Tesra* is enlarged. A 2890-nucleotide sequence was first detected as a transcribed sequence by RT-PCR. 5′RACE was performed with three primers (GSP1--GSP3), and 3′RACE was performed with GSP4 and GSP5 primers. The resulting RACE products are indicated by horizontal lines. (B) 5′-end variations of *Tesra* determined by 5′RACE. A sequence around the 5′ end of *Tesra* that overlaps with the 3′ untranslated region of the *Prss44/Tessp-4* gene is shown. The number of nucleotides between each sequence array is presented below. A specific band was obtained by 5′RACE, and 17 subclones were sequenced. The position of the 5′ end of each subclone is indicated by the red letters and the bent arrows with the number of subclones. Five TSSs were detected, and the most upstream adenine was determined to be a main TSS (indicated by a red arrow). (C) 3′ end of *Tesra* determined by 3′RACE. A specific band was obtained by 3′RACE, and 10 subclones were checked by DNA sequencing. In all subclones, an adenine was identified as a main transcriptional termination site, as indicated by a red letter and a vertical line.](ioy230fig1){#fig1}

RACE analyses were performed to determine the 5′- and 3′-ends of *Tesra*. In 5′RACE experiments, one specific band was obtained after the second PCR, and five different transcriptional start sites (TSSs) were detected by sequencing of 17 subclones. Since 10 of the subclones showed an adenine as the TSS, we defined it as a major TSS of *Tesra* (Figure [1B](#fig1){ref-type="fig"}, red bent arrow). By 3′RACE, one band was amplified in the second PCR, and a single transcriptional termination site was detected 4236 bp downstream of *Prss44/Tessp-4* as a result of sequencing of 10 subclones (Figure [1C](#fig1){ref-type="fig"}). Consequently, the full length of *Tesra* was 4435 nucleotides (DDBJ/EMBL/GenBank accession number: [LC406701](LC406701)). It contained no intron and was presumed to have a poly(A)-tail because some subclones contained a chain of adenine nucleotides longer than oligo(dT). Interestingly, 199 bp of the full length of *Tesra* overlapped with the *Prss44/Tessp-4* gene. Thus, a novel lncRNA, *Tesra*, was transcribed from the *Prss/Tessp* locus, and the full-length sequence was determined.

Expression and localization of *Tesra* {#sec3-2}
--------------------------------------

We examined the tissue specificity of *Tesra* by RT-PCR using eight mouse tissues. *Tesra* showed testis-specific expression as did the *Prss/Tessp* genes (Figure [2A](#fig2){ref-type="fig"}) \[[@bib46]\]. We next investigated the cell type specificity of *Tesra* in the testis, which contained three kinds of cells: germ cells, Sertoli cells, and Leydig cells. We prepared three fractions that were enriched in each type of cells. The Sertoli cell fraction was prepared by primary culture and basically contained no other types of cells. The germ and Leydig cell fractions were prepared from adult testes, and the major contaminants were Sertoli cells and germ cells, respectively. *Tesra* was detected in germ and Leydig cell fractions by RT-PCR but not in the Sertoli cell fraction (Figure [2B](#fig2){ref-type="fig"}), suggesting that germ and Leydig cells express *Tesra*.

![Expression pattern of *Tesra*. (A) Tissue specificity of *Tesra*. Eight mouse tissues, as indicated, were collected from adult mice and used for RT-PCR. Reverse transcription was performed by using the oligo(dT) primer with (RT+) or without reverse transcriptase (RT--). *Gapdh* was detected as an internal control. The cycle number of each reaction is indicated in parenthesis. (B) Cell type specificity of *Tesra* in the testis. Mouse germ, Sertoli, and Leydig cell fractions were prepared and used for RT-PCR. Germ cells and Leydig cells were collected from adult mouse testes, while Sertoli cells were collected from 7- to 12-day-old testes and cultured for several days. The experiment was done and the data are presented as in (A). (C) Subcellular localization of *Tesra* in mouse male germ cells. Germ cells were collected and fractionated into nuclear and cytoplasmic fractions, and total RNAs were purified from both fractions. *Gapdh* was a positive control, in which both forward and reverse primers were designed within exon 6 of the gene. RT-PCR was done and the data are presented as in (A). The *Tesra* transcript was detected in both nuclear and cytoplasmic fractions. (D) *Tesra* expression during postnatal testis development. Mouse testes at postnatal days 7, 14, 21, 28, and 56 were collected, and total RNAs were purified and used for qRT-PCR analysis. The housekeeping *Aip* gene was examined as an internal control. The level of *Tesra* was normalized to *Aip*, and the value at day 7 was set to 1.0. The data are presented as means ± SD from three independent experiments, and the statistical significance was analyzed by one-way ANOVA followed by the Tukey post hoc test. \**P* \< 0.05. \*\**P* \< 0.01.](ioy230fig2){#fig2}

We then investigated the subcellular localization of *Tesra*. We prepared total RNAs from nuclear and cytoplasmic fractions from germ cells and performed RT-PCR. *Tesra* transcripts were present in both the nuclear and cytoplasmic fractions (Figure [2C](#fig2){ref-type="fig"}). We also investigated the expression pattern in the mouse testis at postnatal days 7, 14, 21, 28, and 56. The *Tesra* signal was detected at a low level on postnatal day 7, and the expression level dramatically increased to a peak in the period from day 14 to day 21 (Figure [2D](#fig2){ref-type="fig"}). The timing of an increase in *Tesra* transcription coincided with activation of the *Prss/Tessp* genes at the pachytene spermatocyte stage \[[@bib46]\].

We further assessed *Tesra* expression during meiosis by in situ hybridization using the highly sensitive TSA method. Many more small dot-like signals were detected by the antisense probe than by the sense probe, and the signals were dispersed throughout seminiferous tubules (Figure [3A--D](#fig3){ref-type="fig"}). At seminiferous epithelial stage IV--V, many signals were observed in the nuclei and cytoplasm of early to mid pachytene spermatocytes, and spermatogonia and round spermatids also contained dots in their nuclei and cytoplasm (Figure [3A and G](#fig3){ref-type="fig"}). At stage IX, the number of signals was increased, and more dots were localized in the nuclei of late pachytene spermatocytes (Figure [3B and G](#fig3){ref-type="fig"}). At stage X, the number of signals was slightly decreased, but red dots were still present in the nuclei and cytoplasm of pachytene spermatocytes (Figure [3C](#fig3){ref-type="fig"}). Elongating spermatids also contained signals, but the distribution was biased toward the cytoplasm (Figure [3G](#fig3){ref-type="fig"}). In interstitial regions, positive signals were present in Leydig cells, mostly in the cytoplasm (Figure [3E and F](#fig3){ref-type="fig"}). These results indicated that *Tesra* was localized in both the nuclei and cytoplasm of spermatogonia, primary spermatocytes, and round spermatids and in the cytoplasm of elongating spermatids and Leydig cells. The number of signals was large at late epithelial seminiferous stages, especially in late pachytene spermatocytes compared to other cell types. Of note, *Tesra* signals were also observed in the lumen of seminiferous tubules, and similar results were obtained by using another antisense probe for *Tesra* (data not shown).

![Localization of *Tesra* in the mouse testis. In situ hybridization was performed in adult mouse testes by using the TSA system. Sections of mouse testes (7 μm) were hybridized with a DIG-labeled sense or antisense probe for *Tesra*. Positive signals were detected by reaction with tyramide-Cy3 (red), and nuclei were stained with Hoechst 33258 and shown as gray. Panels (A--D) show seminiferous tubules at indicated stages, and panels (E) and (F) show Leydig cells. Sections stained with the antisense probe are presented in (A--C) and (E), and those stained with the sense probe are shown in (D) and (F). Sections hybridized with the sense probe showed few signals. With the antisense probe, positive signals were observed in all seminiferous tubules, and localized in the nuclei and/or cytoplasm of spermatogonia, spermatocytes, spermatids, and Leydig cells. Enlarged pictures of each type of meiotic cells that are surrounded with frames, marked as a--d in (A--C), are indicated in (G). SG, spermatogonium; SC, spermatocyte; RS, round spermatid; ES, elongating spermatid. Scale bars, 50 μm.](ioy230fig3){#fig3}

To identify the scattered signals in the entire tubules and in the lumen by in situ hybridization, we tested the possibility that *Tesra* transcripts were present in extracellular regions. We collected the extracellular fraction of a testis, purified total RNA, and investigated *Tesra* expression by qRT-PCR. For comparison, we detected the expression of *lncRNA-HSVIII* which did not show scattered patterns by the method \[[@bib45]\]. As a result, the *Tesra* signal was detected at a 4.6-fold higher level than *lncRNA-HSVIII* in the extracellular fraction whereas germ cells showed 1.8-fold difference (Figure [4A](#fig4){ref-type="fig"}). We then attempted to isolate EV fractions containing exosomes since it has been shown that many extracellular lncRNAs are packaged within EVs to travel into neighboring or distant cells \[[@bib53]\]. We applied the extracellular fraction to size exclusion chromatography and collected 10 fractions by elution. Western blot analysis indicated that a marker protein of exosomes, CD9, was mainly contained in fractions \#6--\#9 (Figure [4B](#fig4){ref-type="fig"}), and the observation of a fraction by an electron microscope showed the presence of an EV (Figure [4C](#fig4){ref-type="fig"}). We purified total RNAs from fractions \#7 and \#8, and the *Tesra* signal was clearly detected by RT-PCR in one of the fractions in duplicate experiments (Figure [4D](#fig4){ref-type="fig"}). Therefore, some of the *Tesra* transcripts were likely to be excluded from the cells and associated with a particular size of EV, which probably resulted in detection of scattered signals by in situ hybridization.

![Extracellular localization of *Tesra*. (A) Expression of *Tesra* in the extracellular fraction (left) and germ cells (right) from adult mouse testes. The extracellular fraction was collected by immersing tissue pieces of adult testes in a cell culture medium, and total RNAs were purified. Germ cells were also investigated to measure the intracellular level. Complementary DNAs were synthesized with a random hexamer for the extracellular fraction and with the oligo(dT) primer for germ cells, and real-time PCR was performed to amplify *Tesra* and *lncRNA-HSVIII*. Since the amplification efficiencies were not so different, the expression levels were directly compared by setting the value of *lncRNA-HSIII* to 1.0. The data are presented as means ± SD from three independent experiments and were analyzed by the Student *t* test. \**P* \< 0.05 relative to the control. (B) Western blot analysis of fractions collected by size exclusion chromatography. The extracellular fraction was applied to the column to separate EVs, and 10 fractions were eluted. A portion of each fraction was subjected to western blot analysis to detect the CD9 protein, a widely used exosome marker. We performed duplicate experiments, and both results are shown. Intense signals were detected in fractions \#6-\#9 of both samples. (C) Electron microscopic observation of an EV. A representative photograph of an EV in a fraction that was obtained by size exclusion chromatography and was positive for CD9. Similar vesicles were observed on the mesh. A scale bar, 100 nm. (D) RT-PCR with exosome fractions. Total RNAs were purified from fractions \#7 and \#8 of both samples in (B), and cDNAs were synthesized with a random hexamer. *Tesra* signals were detected by 37 cycles of PCR and agarose gel electrophoresis. In sample 1, the signal was observed in fraction \#7, and in sample 2, both lanes showed the band, although the signal intensity was much higher in fraction \#8.](ioy230fig4){#fig4}

*Tesra* binds to the *Prss42/Tessp-2* promoter {#sec3-3}
----------------------------------------------

The fact that *Tesra* transcription was increased at a timing similar to that of *Prss/Tessp* gene activation (Figure [2D](#fig2){ref-type="fig"}) and the fact that the transcripts were localized in nuclei of pachytene spermatocytes (Figure [3B and G](#fig3){ref-type="fig"}) indicated that *Tesra* was possibly involved in activation of the *Prss/Tessp* genes during meiosis. To verify this possibility, we investigated whether the *Tesra* transcript interacted with a promoter region of any of the *Prss/Tessp* genes. For this purpose, we attempted to reveal the genome occupancy of *Tesra* at the *Prss/Tessp* locus (including three other *Prss* genes downstream of *Prss43/Tessp-3*) by performing a ChIRP assay \[[@bib54],[@bib55]\]. We collected male germ cells from 21- to 22-day-old mice and hybridized the sonicated chromatin with biotinylated tiling oligos because the expression level of *Tesra* was the highest at these stages (Figure [2D](#fig2){ref-type="fig"}). As a control, we prepared an RNase(+) sample that was treated with RNase in the hybridization reaction to reduce *Tesra* transcripts. We purified DNAs bound to the oligos and amplified genomic regions at the *Prss/Tessp* locus by qPCR. *Rec8* and *B2m* promoters on different chromosomes from the *Prss/Tessp* cluster were examined as negative controls, and the occupancy level at the *Rec8* promoter was set to 1.0. Co-isolation of *Tesra* transcripts with bound chromatin was confirmed by RNA isolation and qRT-PCR after ChIRP (data not shown).

Most regions showed no significant difference in genomic occupancy compared with the *Rec8* promoter, but the *Prss42/Tessp-2* promoter showed a significantly higher level of genome occupancy (Figure [5](#fig5){ref-type="fig"}, black bars). Although the level was not significantly different from *Rec8* promoter, the region transcribed into *Tesra* exhibited slightly higher occupancy. This was considered to be an artifact by direct interaction of tiling oligos with genome DNA, as evidenced by the control data (RNase+) showing a clear peak at this region (Figure [5](#fig5){ref-type="fig"}, white bars). In contrast, no peak was observed at the *Prss42/Tessp-2* promoter in the RNase(+) sample, indicating actual binding of *Tesra* transcripts to this region. Thus, the *Tesra* transcript interacts with the *Prss42/Tessp-2* promoter at the *Prss/Tessp* locus in mouse germ cells, suggesting that *Tesra* plays a role in regulation of the expression of the *Prss42/Tessp-2* gene.

![*Tesra* occupancy at the *Prss/Tessp* locus. ChIRP-qPCR for *Tesra* in mouse testicular germ cells was performed. Germ cells were collected from 21- to 22-day-old mouse testes, and nuclear extracts were prepared. Sonicated chromatin was hybridized with biotinylated tiling oligo probes, and the bound chromatin was collected by streptavidin beads. Purified genome DNAs were investigated by qPCR. *Rec8* and *B2m* promoters that were located on different chromosomes from the *Prss/Tessp* cluster were amplified as negative controls. The value was normalized to that of the input sample, which was kept before hybridization, and further normalized to the level at the *Rec8* promoter (=1.0). The relative chromatin enrichment at each position is shown by the black bars. The white bars show the data from the experiment with RNase in hybridization buffer as a negative control. Positions of amplicons are indicated by arrows below the graph. The data are presented as means ± SD from three independent experiments and were analyzed by one-way ANOVA followed by the Tukey post hoc test. \**P* \< 0.05 compared to other regions.](ioy230fig5){#fig5}

*Prss42/Tessp-2* gene activation by *Tesra* {#sec3-4}
-------------------------------------------

To assess the function of *Tesra* in *Prss42/Tessp-2* regulation, we overexpressed *Tesra* in a mouse hepatic tumor cell line, Hepa1--6, that endogenously expressed *Prss42/Tessp-2* mRNA (Figure [6A](#fig6){ref-type="fig"}). We transfected Tesra-OE or a control vector, and after selection of successfully transfected cells with G418, endogenous *Prss42/Tessp2* expression was evaluated by qRT-PCR. *Tesra* expression was dramatically induced in the cells with *Tesra*-OE compared with that in the control cells (Figure [6B](#fig6){ref-type="fig"}), and the overexpression significantly increased endogenous *Prss42/Tessp-2* expression (Figure [6C](#fig6){ref-type="fig"}).

![Overexpression of *Tesra* increases *Prss42/Tessp-2* expression and promoter activity. (A) Endogenous expression of *Prss/Tessp* cluster genes and *Tesra* in Hepa1--6 cells. qRT-PCR was performed with total RNAs from Hepa1--6 cells. Reverse transcription was done by using the oligo(dT) primer, and the *Aip* gene was examined as an internal control. Expression levels were normalized to *Aip*. (B) Successful overexpression of *Tesra*. Tesra-OE or the control vector was transiently transfected into Hepa1--6 cells, and after selection with G418, total RNA was purified from each sample. Complementary DNA was synthesized with the oligo(dT) primer, and PCR was conducted to detect *Tesra* and *Gapdh* expression. The cycle number is shown in parenthesis. A representative result from three experiments is shown. We could not see any difference among the three data sets. (C) Relative expression of *Prss42/Tessp-2* mRNA by overexpression of *Tesra*. qRT-PCR was performed with the cDNAs prepared in (B). Data normalization was done by using *Aip* as an internal control. Transient overexpression of *Tesra* significantly increased *Prss42/Tessp-2* expression in Hepa1--6 cells. The data are presented as means ± SD from three independent experiments and were analyzed by the Student *t* test. \**P* \< 0.05 relative to the control. (D) Luciferase assay in Hepa1--6 cells transiently transfected with Tesra-OE. T-2pro-luc was transiently co-transfected with Tesra-OE or the control vector into Hepa1--6 cells, and luciferase activity was measured 2 days later. Relative luciferase activity is presented by setting the activity with the control to 1.0. *Tesra* overexpression significantly increased *Prss42/Tessp-2* promoter activity. The data are presented as means ± SD from three independent experiments and were analyzed by the Student *t* test. \*\*\**P* \< 0.001 relative to the control.](ioy230fig6){#fig6}

We then carried out a transient reporter gene assay to determine whether *Tesra* increased *Prss42/Tessp-2* promoter activity. We prepared a construct in which the luciferase gene was driven by a 1.6-kb *Prss42/Tessp-2* promoter (T-2pro-luc), and co-transfected it with Tesra-OE into Hepa1--6 cells. As a result of measurement of luciferase activity 48 h later, *Prss42/Tessp-2* promoter activity was significantly increased compared to that in the case of co-transfection with the control vector (Figure [6D](#fig6){ref-type="fig"}). These data suggested that *Tesra* contributed to activation of the *Prss42/Tessp-2* gene by increasing *Prss42/Tessp-2* promoter activity.

Co-activation of *Prss42/Tessp-2* promoter activity by an enhancer and *Tesra* {#sec3-5}
------------------------------------------------------------------------------

We previously reported that upstream and downstream sequences of *lncRNA-HSVIII* possessed enhancer activity for *Prss42/Tessp-2* \[[@bib45]\] (Figure [7A](#fig7){ref-type="fig"}). We finally investigated whether *Tesra* was functionally related to these enhancers for *Prss42/Tessp-2* activation. To answer this question, we established *Tesra*-inducible stable cells by the Tet-on system in Hepa1--6 cells. The stable cell line was established by co-transfection of Tesra-tet-on with other required vectors and selection with G418. Dox treatment and qRT-PCR verified that *Tesra* transcription was about 80-fold increased by culture for 24 h (Figure [7B](#fig7){ref-type="fig"}).

![*Tesra* co-operatively increases *Prss42/Tessp-2* promoter activity with the downstream enhancer. (A) A schematic view of the *Prss/Tessp* locus indicating positions of the enhancers. The *Prss/Tessp* locus is depicted as in Figure [1A](#fig1){ref-type="fig"}. Two potential enhancers we identified before \[[@bib45]\] are indicated with white boxes marked as "up" and "down." (B) Successful induction of *Tesra* transcription in stable Hepa1--6 cells. We established stable Hepa1--6 cells that were responsive to Dox to induce *Tesra* transcription by the Tet-on system. Dox was added to the cells, and total RNAs were collected 24 h later. qRT-PCR was performed and the data are presented as in Figure [2D](#fig2){ref-type="fig"}. *Tesra* transcription was significantly induced by the addition of Dox. The data are presented as means ± SD from three independent experiments and were analyzed by the Student *t* test. \*\**P* \< 0.01 relative to Dox-. (C) Luciferase assay in stable *Tesra*-inducible Hepa1--6 cells. Each construct indicated on the left was transiently transfected into the cells. Dox was added 24 h after the transfection, and luciferase activity was measured after another 24 h (black bars). We also prepared cells that were transfected with luciferase constructs but not treated with Dox (white bars). The activity in the cells with T-2pro-luc without Dox was set to 1.0. The data are presented as means ± SD from three independent experiments, and the statistical significance was analyzed by one-way ANOVA followed by the Tukey post hoc test. \**P* \< 0.05. \*\**P* \< 0.01.](ioy230fig7){#fig7}

We transfected T-2pro-luc, T-2pro-luc-up, or T-2pro-luc-down constructs into the *Tesra*-inducible stable cell line and added Dox 24 h after the transfection. After another 24 h, we measured luciferase activity. Without Dox, we confirmed enhancer activity of both upstream and downstream sequences for the *Prss42/Tessp-2* promoter (Figure [7C](#fig7){ref-type="fig"}). The promoter activity was significantly increased by about 1.3-fold with T-2pro-luc-up and by about 1.7-fold with T-2pro-luc-down (Figure [7C](#fig7){ref-type="fig"}, white bars). By the addition of Dox, we observed a further increase in *Prss42/Tessp-2* promoter activity with T-2pro-luc-down; the activity was significantly increased by 2.2-fold (Figure [7C](#fig7){ref-type="fig"}, black bars of T-2pro-luc vs T-2pro-luc-down). In contrast, promoter activity was not significantly changed in the cells with T-2pro-luc-up by Dox treatment (Figure [7C](#fig7){ref-type="fig"}, black bars of T-2pro-luc vs T-2pro-luc-up). These results indicated that *Tesra* and the downstream enhancer could cooperatively but independently increase *Prss42/Tessp-2* promoter activity.

Discussion {#sec4}
==========

In this study, we identified a novel mouse testis-specific lncRNA, *Tesra*, that was expressed in both germ cells and Leydig cells but not in Sertoli cells. The subcellular localization was shown by in situ hybridization to be different depending on the cell type. Spermatogonia, primary spermatocytes, and round spermatids contained the *Tesra* transcript in both the nuclei and cytoplasm, while it was mostly present in the cytoplasm of elongating spermatids and Leydig cells. The number of *Tesra* signals was larger in pachytene spermatocytes than in other types of germ cells, being in agreement with the increase in *Tesra* expression in the testis between day 14 and day 21, when germ cells reach the stage of pachytene spermatocytes. Although some nuclear and cytoplasmic signals detected by in situ hybridization might be derived from extracellular transcripts, our data indicated the following expression pattern. *Tesra* transcription begins in spermatogonia at a low level and is dramatically enhanced when germ cells become mid or late pachytene spermatocytes. During this period, *Tesra* transcripts are localized in both the nuclei and cytoplasm, and such localization is maintained in round spermatids. In spermiogenesis, *Tesra* transcripts come to be localized in the cytoplasm of elongating spermatids. These findings suggest that *Tesra* has multiple functions during spermatogenesis.

Although we focused on nuclear *Tesra* in this study, in situ hybridization showed dot-like signals in cytoplasm, suggesting that *Tesra* transcripts are associated with some specific cytoplasmic structures. There are several granular structures composed of ribonucleoproteins in cytoplasm of mammalian cells. Stress granules appear in response to a variety of stress to repress translation \[[@bib56]\], and similar RNA granules were observed in oocytes to control a timing of translation during oocyte maturation \[[@bib57]\]. A processing body is another RNA granule which is related to translational repression and mRNA decay \[[@bib58]\]. Because several genes were reported to be translationally arrested during male meiosis \[[@bib59],[@bib60]\], cytoplasmic *Tesra* may also form a ribonucleoprotein complex and function in the regulation of translation.

It is interesting that *Tesra* transcipts were detected in extracellular fractions. We concluded extracellular localization based on (1) observation of scattered signals by in situ hybridization; (2) detection of *Tesra* in the extracellular fraction at a higher level than that of *lncRNA-HSVIII*, which never showed scattered signals, especially in the lumen \[[@bib45]\]; and (3) detection of *Tesra* in some of the EV fractions. All of these findings support the existence of *Tesra* as extracellular RNA in the mouse testis, although *Tesra* may be present as fragmented RNAs rather than the full length as evidenced by more efficient detection of extracellular *Tesra* transcripts with the primer pair "*Tesra* exosome" than "*Tesra* PCR" (data not shown). Because only one of the two EV fractions showed the clear *Tesra* signal by RT-PCR, this transcript is probably contained in a specific population of EVs. In addition, the *Tesra* level relative to *lncRNA-HSVIII* in extracellular fractions was higher than that within germ cells, suggesting a specific mechanism of preferentially secreting *Tesra* out of the cell. It is known that the protein or miRNA profiling in EVs is different depending on the cell type or external stimulus \[[@bib61],[@bib62]\] and the packaging of proteins or RNAs into EVs is a selective process \[[@bib63],[@bib64]\]. In case of mRNAs, specific nucleotide sequences were reported to be involved in this selection \[[@bib65]\], and some lncRNAs were suggested to be selectively sorted into EVs \[[@bib66]\]. Therefore, *Tesra* transcripts may be packaged into EVs and secreted from germ cells by some specific mechanism.

Recent studies have shown that several lncRNAs are actually released into extracellular regions and enclosed within EVs such as exosomes \[[@bib53],[@bib67]\]. So far, many extracellular lncRNAs have been reported to come from cancerous tissues, but nontumor tissues also secrete lncRNAs by EVs \[[@bib68]\], suggesting the presence of more EV-associated lncRNAs in normal tissues. In the case of *Tesra*, its co-existence with an exosome marker strongly suggests that *Tesra* transcripts are associated with a particular size of EVs. However, the function of extracellular *Tesra* is unclear. Since some exosomal RNAs are related to cell-to-cell communication in distant or neighboring cells \[[@bib53]\], it is possible that extracellular *Tesra* contributes to the progression of spermatogenesis through controlling germ cell-to-germ cell communication. More studies are necessary for elucidating the significance of extracellular *Tesra*.

To reveal the mechanism of transcriptional activation in primary spermatocytes, we used a Hepa1--6 cell line which was derived from a mouse hepatoma \[[@bib69],[@bib70]\] instead of a spermatocyte-derived cell line, GC-2spd(ts) \[[@bib71]\], because Hepa1--6 endogenously expressed *Prss/Tessp* cluster genes but GC-2spd(ts) did not (data not shown). However, while tumor cells were reported to partly share characteristics with testicular cells \[[@bib72],[@bib73]\], they are different from spermatogenetic cells, and indeed, the expression levels of *Prss/Tessp* genes in Hepa1--6 cells were lower than those in the testis. This indicates the limitation of using Hepa1--6 cells for functional experiments, and our data suggest a potential function of *Tesra*. In vivo studies need to be done for concluding the function.

We focused on the function of *Tesra* in the nuclei of pachytene spermatocytes. In general, nuclear lncRNAs are often involved in transcriptional regulation of their neighboring genes \[[@bib74]\], and the *Prss/Tessp* cluster genes are activated in pachytene spermatocytes. We therefore investigated the involvement of *Tesra* in their transcriptional activation. We obtained the following evidence that supported a positive role of *Tesra* in regulation of the *Prss42/Tessp-2* gene. First, a ChIRP assay showed that *Tesra* significantly interacted with chromatin at the *Prss42/Tessp-2* promoter in germ cells (Figure [5](#fig5){ref-type="fig"}). This confirmed the in vivo interaction of the *Tesra* transcript with chromatin at the *Prss42/Tessp-2* promoter. Second, *Tesra* significantly increased endogenous *Prss42/Tessp-2* gene expression by transient overexpression in Hepa1--6 cells (Figure [6C](#fig6){ref-type="fig"}). Third, a transient reporter gene assay showed that the overexpression also increased *Prss42/Tessp-2* promoter activity in Hepa1--6 cells (Figure [6D](#fig6){ref-type="fig"}). These findings suggest that *Tesra* contributes to transcriptional activation of the *Prss42/Tessp-2* gene by enhancing promoter activity.

How does *Tesra* increase *Prss42/Tessp-2* promoter activity? Many nuclear lncRNAs that participate in transcriptional activation recruit histone modifiers or transcription factors to chromatin regions of target genes \[[@bib77]\]. For example, *GClnc1* interacts with WDR5 and KAT2A, which form an epigenetic modification complex, to specify the histone modification pattern of target genes for transcriptional activation \[[@bib78]\]. *RMST* interacts with hnRNPA2/B1 and SOX2 and plays a critical role in the binding of SOX2 to target gene promoters \[[@bib79]\]. Similarly to these lncRNAs, *Tesra* may recruit transcription factors or histone modification enzymes to the *Prss42/Tessp-2* promoter region. Alternatively, *Tesra* may function as a scaffold that interacts with multiple protein complexes, as reported for *HOTTIP* associated with the WDR5/MLL1 chromatin-modifying complex \[[@bib80]\] and *Rmrp* associated with the DDX5--RORγt complex \[[@bib81]\]. Further studies are required for understanding the detailed molecular mechanism concerning the function of *Tesra*.

Long noncoding RNAs often collaborate with enhancers to activate their target genes. For instance, one class of lncRNAs, enhancer-derived RNAs, is unidirectionally or bidirectionally transcribed at enhancer regions and mediates histone modification for active chromatin \[[@bib82],[@bib83]\] and chromatin looping between the enhancer and promoter \[[@bib84],[@bib85]\]. Some lncRNAs are not transcribed at enhancers but still affect the looping between distal enhancers and promoters \[[@bib43]\]. In any case, these functional lncRNAs regulate the transcription of their target genes through their action on enhancers, and lncRNAs are therefore mostly considered to facilitate enhancer activity. In contrast, the transcriptional activation of *Prss42/Tessp-2* by *Tesra* and the enhancer appears to be different from such examples. We previously reported enhancer activity of upstream and downstream sequences of *lncRNA-HSVIII* \[[@bib45]\], but *Tesra* was transcribed at a distal region from these enhancers. In addition, a luciferase assay in a hepatoma cell showed that both *Tesra* and two enhancers could increase *Prss42/Tessp-2* promoter activity independently (Figure [7](#fig7){ref-type="fig"}). Each enhancer could individually activate the promoter, and *Tesra* also activated *Prss42/Tessp-2* transcription in the absence of the enhancers. The downstream enhancer and *Tesra* just co-functioned for increasing *Prss42/Tessp-2* promoter activity when they co-existed. These findings indicate that *Tesra* and the enhancer are not interdependent. To the best of our knowledge, there has been no report showing such a relationship between an lncRNA and an enhancer, and our data therefore suggest a novel mechanism of gene activation by an enhancer and an lncRNA.

Out of the two potential enhancers, *Tesra*, collaborated only with the downstream enhancer because the induction of *Tesra* transcription additively increased *Prss42/Tessp-2* promoter activity with the downstream sequence but not with the upstream sequence (Figure [7](#fig7){ref-type="fig"}). Consistent with those findings, it was actually the downstream sequence that was shown to interact with the *Prss42/Tessp-2* promoter by a chromosome conformation capture assay \[[@bib45]\]. Therefore, the two enhancers may function redundantly; the downstream enhancer may mainly function in the transcriptional activation of *Prss42/Tessp-2*, but when it is impaired, the gene may be activated by the upstream enhancer. Such a mechanism might have evolved due to the extreme importance of spermatogenesis for animals.

In combination with our previous study \[[@bib45]\], we revealed that two factors potentially contribute to *Prss42/Tessp-2* transcriptional activation. First, a downstream region of *lncRNA-HSVIII*, which interacted with the *Prss42/Tessp-2* promoter by looping out the intervening region, could function as an enhancer. Second, lncRNA *Tesra*, which was transcribed downstream of *Prss44/Tessp-4*, bound to chromatin at the *Prss42/Tessp-2* promoter to potentially increase its activity. Both factors activated *Prss42/Tessp-2* transcription through increasing *Prss42/Tessp-2* promoter activity. From these findings, we propose the following hypothetical model for *Prss42/Tessp-2* gene activation during meiosis (Figure [8](#fig8){ref-type="fig"}). When spermatogonia divide into primary spermatocytes, the chromatin at the *Prss42/Tessp-2* promoter begins to interact with the *lncRNA-HSVIII* region at its 3′ end, and *Prss42/Tessp-2* transcription is initiated. This interaction is maintained and even strengthened in late pachytene spermatocytes or secondary spermatocytes, and the downstream enhancer of *lncRNA-HSVIII* comes to physically contact the *Prss42/Tessp-2* promoter to increase its transcriptional activity. Meanwhile, at a timing similar to that of chromatin interaction, *Tesra* transcripts are accumulated in the nuclei of pachytene spermatocytes and bind to the *Prss42/Tessp-2* promoter directly or indirectly to positively affect its activity. These events may lead to a high level of transcriptional activation of the *Prss42/Tessp-2* gene.

![A hypothetical model for *Prss42/Tessp-2* transcriptional activation. This figure indicates the hypothesized mechanism of *Prss42/Tessp-2* gene activation based on our data. When spermatogonia divide into primary spermatocytes, the chromatin at the enhancer downstream of *lncRNA-HSVIII* begins to interact with that at the *Prss42/Tessp-2* promoter, and thereby the enhancer is allowed to activate *Prss42/Tessp-2* transcription. At a similar timing, *Tesra* transcripts are accumulated in the nuclei of primary spermatocytes and bind to chromatin at the *Prss42/Tessp-2* promoter. The transcription level of *Prss42/Tessp-2* is substantially enhanced by these two elements. There must be some proteins binding to *Tesra* transcripts and/or to the *Prss42/Tessp-2* promoter.](ioy230fig8){#fig8}

Recent studies have revealed numerous lncRNAs in each stage of spermatogenesis, but only a few studies have shown the functions of testicular lncRNAs. Only a few mammalian lncRNAs have been found to be critical in male germ cell development, especially in the meiotic stage. For instance, testis-specific X-linked (*Tsx*), which is an X-linked lncRNA and is specifically expressed in pachytene spermatocytes, was shown to be crucial for the progression of meiosis and to possibly regulate *Tsix* during spermatogenesis \[[@bib86]\]. *R53* containing a SINE-B1 motif is expressed mainly in the nuclei of spermatocytes, and its reduction causes abnormal upregulation of the expression of *Tnp1, Tnp2,* and *Prm1* genes, resulting in impairment of meiosis \[[@bib87]\]. *Tslrn1* is highly expressed in mouse primary spermatocytes, and mice with its knockout showed a significant reduction in spermatozoa \[[@bib20]\]. Our group identified *lncRNA-Tcam1* that is expressed at a high level in spermatocytes and suggested that it regulates immune-related genes for immune response during meiosis \[[@bib88]\]. Downregulation of *mrhl* RNA is required for activation of Wnt signaling and the entry of spermatogonia into meiosis \[[@bib89]\]. While these findings indicate the significance of lncRNAs in spermatogenesis, more lncRNAs have to be functionally analyzed when we consider the large number of lncRNAs identified in the testis. We successfully extended the knowledge of testicular lncRNAs by the present study.

In summary, we revealed the expression pattern and suggested the function of a novel lncRNA, *Tesra. Tesra* potentially contributes to transcriptional activation of the *Prss42/Tessp-2* gene, and due to the significant role of this gene in the progression of meiosis from secondary spermatocytes to round spermatids \[[@bib46]\], this lncRNA may play a role in spermatogenesis. Our results also suggested a novel relationship between an lncRNA and an enhancer, contribute to an understanding of how spermatogenesis is regulated, and provide an insight into the function of an lncRNA in reproduction.
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Click here for additional data file.
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